Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery

Código QR

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery

Timothy L Comstock1 Michael R Paterno1 Angele Singh1 Tara Erb1 Elizabeth Davis21Bausch and Lomb Inc., Rochester, NY, USA; 2Minnesota Eye Consultants, Bloomington, MN, USABackground: To compare the safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% (LE ointment), a new topical oint...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Timothy L Comstock, Michael R Paterno, Angele Singh, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ab92cd3cc6ee4e779872febd40028976
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard JD, et al.
Publicado: (2014)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong R, et al.
Publicado: (2012)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi MA
Publicado: (2018)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe ZT, et al.
Publicado: (2013)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey MJ, et al.
Publicado: (2013)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard JD, et al.
Publicado: (2019)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong R, et al.
Publicado: (2019)

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
por: Salinger CL, et al.
Publicado: (2015)

Difluprednate ophthalmic emulsion 0.05% (Durezol&reg;) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Stephen Smith, et al.
Publicado: (2010)

Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery
por: Pirouzian A, et al.
Publicado: (2014)

Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
por: Mifflin MD, et al.
Publicado: (2017)

Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery
por: Reddy RK, et al.
Publicado: (2011)

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana C, et al.
Publicado: (2020)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci FA Jr, et al.
Publicado: (2015)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Efficacy and safety of 0.5% levobupivacaine versus 0.5% bupivacaine for peribulbar anesthesia
por: Pacella E, et al.
Publicado: (2013)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang XJ, et al.
Publicado: (2011)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: William Stringer, et al.
Publicado: (2010)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)

Tetracaine 0.5% eyedrops with or without lidocaine 2% gel in topical anesthesia for cataract surgery
por: Anthoula T Tsoumani, et al.
Publicado: (2010)

Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
por: Kim T, et al.
Publicado: (2018)

Safety, efficacy, and intraoperative characteristics of DisCoVisc and Healon ophthalmic viscosurgical devices for cataract surgery
por: Modi SS, et al.
Publicado: (2011)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra R, et al.
Publicado: (2012)

Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci Jr FA, et al.
Publicado: (2016)

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
por: Brooks CC, et al.
Publicado: (2020)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Katelin Quantz, et al.
Publicado: (2021)

Journal of ophthalmic inflammation and infection
Publicado: (2011)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Preparation and characterization of a new graphite superconductor: Ca0.5Sr0.5C6
por: Saki Nishiyama, et al.
Publicado: (2017)

Light-induced enhancement of superconductivity in iron-based superconductor FeSe0.5Te0.5
por: Kazuki Isoyama, et al.
Publicado: (2021)

Li(V0.5Ti0.5)S2 as a 1 V lithium intercalation electrode
por: Steve J. Clark, et al.
Publicado: (2016)

Magnetic breakdown in 2D hole system at GaAs/Al0.5Ga0.5As heterointerface
por: Minina, N., et al.
Publicado: (2005)